Due to the heterogeneity of pathogenic mechanisms operating in psoriasis, and to the variety of molecular cascades potentially activated by proinflammatory cytokines, a combination of JAK inhibitors and TNF-α or IL-17 blockers might elicit more favorable and efficacious therapeutic effects in psoriatic patients, by intercepting and blocking inflammatory responses at multiple levels. This evidence concerns the gene IL17A and psoriasis.